Skip to Main content Skip to Navigation
Journal articles

Restriction Factors Against Recombinant Adeno-associated Virus Vectormediated Gene Transfer in Dystrophin-deficient Muscles

Abstract : Despite the unprecedented beneficial effects of rAAV gene therapy in animal models of Duchenne muscular dystrophy (DMD), the need to inject large amounts of vector in vivo to improve phenotype raises obvious biosafety concerns. While rAAV vectors generally exhibit a good safety profile, specific pathological phenotypes such as those observed in dystrophin-deficient muscles may promote immunotoxic/genotoxic effects. Increasing the therapeutic index of rAAV in DMD muscles by reducing the effective dose could be a pivotal means of ensuring efficient clinical translation. This requires a comprehensive understanding of the rAAV transduction process, which is almost always studied in non-pathological tissues or in vitro. In this review, we focus on the molecular fate of rAAV after injection, and how the individual stages of transduction could be affected in the context of DMD.
Complete list of metadatas

Cited literature [225 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02913088
Contributor : Jean-Baptiste Dupont <>
Submitted on : Friday, August 7, 2020 - 2:37:32 PM
Last modification on : Wednesday, September 2, 2020 - 1:38:19 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Jean-Baptiste Dupont. Restriction Factors Against Recombinant Adeno-associated Virus Vectormediated Gene Transfer in Dystrophin-deficient Muscles. Current Gene Therapy, Bentham Science Publishers, 2016, 1 (3), pp.168-183. ⟨10.2174/1566523216666160428104325⟩. ⟨inserm-02913088⟩

Share

Metrics

Record views

78